Published in Cancer Res on October 15, 1996
Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev (2008) 4.80
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine (2008) 2.16
The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine (2012) 1.83
Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials (2008) 1.70
Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomedicine (2010) 1.55
Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J (2006) 1.52
Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials (2010) 1.42
Magnetic nanoparticles: surface effects and properties related to biomedicine applications. Int J Mol Sci (2013) 1.37
Magnetic nanoparticles as targeted delivery systems in oncology. Radiol Oncol (2011) 1.19
Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles. FASEB J (2007) 1.14
The Behaviors of Ferro-Magnetic Nano-Particles In and Around Blood Vessels under Applied Magnetic Fields. J Magn Magn Mater (2011) 1.12
Physical methods of nucleic acid transfer: general concepts and applications. Br J Pharmacol (2009) 1.09
Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. ACS Nano (2010) 1.02
Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int J Nanomedicine (2007) 1.01
Magnetic nanoparticle drug carriers and their study by quadrupole magnetic field-flow fractionation. Mol Pharm (2009) 0.99
Oh the irony: Iron as a cancer cause or cure? Biomaterials (2011) 0.98
Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery. Int J Mol Sci (2015) 0.96
Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials (2011) 0.95
Towards dynamic control of magnetic fields to focus magnetic carriers to targets deep inside the body. J Magn Magn Mater (2009) 0.95
Magnetic nanoparticle transport within flowing blood and into surrounding tissue. Nanomedicine (Lond) (2010) 0.93
Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int J Nanomedicine (2012) 0.92
Recent advances in superparamagnetic iron oxide nanoparticles for cellular imaging and targeted therapy research. Curr Pharm Des (2013) 0.92
A combined theoretical and in vitro modeling approach for predicting the magnetic capture and retention of magnetic nanoparticles in vivo. J Control Release (2011) 0.92
Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. Int J Mol Epidemiol Genet (2011) 0.90
Enabling anticancer therapeutics by nanoparticle carriers: the delivery of Paclitaxel. Int J Mol Sci (2011) 0.87
Magnetic targeting of iron-oxide-labeled fluorescent hepatoma cells to the liver. Eur Radiol (2009) 0.87
Apoferritin modified magnetic particles as doxorubicin carriers for anticancer drug delivery. Int J Mol Sci (2013) 0.87
Fabrication of Fe3O4@mSiO2 Core-Shell Composite Nanoparticles for Drug Delivery Applications. Nanoscale Res Lett (2015) 0.84
Open challenges in magnetic drug targeting. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.84
A dynamic magnetic shift method to increase nanoparticle concentration in cancer metastases: a feasibility study using simulations on autopsy specimens. Int J Nanomedicine (2011) 0.84
Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors. Int J Nanomedicine (2014) 0.84
Optimal Halbach Permanent Magnet Designs for Maximally Pulling and Pushing Nanoparticles. J Magn Magn Mater (2011) 0.83
Design and Application of Magnetic-based Theranostic Nanoparticle Systems. Recent Pat Biomed Eng (2013) 0.83
A Two-Magnet System to Push Therapeutic Nanoparticles. AIP Conf Proc (2010) 0.83
Targeting of systemically-delivered magnetic nanoparticle hyperthermia using a noninvasive, static, external magnetic field. Proc SPIE Int Soc Opt Eng (2013) 0.82
Triple-Modal Imaging of Magnetically-Targeted Nanocapsules in Solid Tumours In Vivo. Theranostics (2016) 0.81
Doxorubicin-modified magnetic nanoparticles as a drug delivery system for magnetic resonance imaging-monitoring magnet-enhancing tumor chemotherapy. Int J Nanomedicine (2016) 0.80
Polymer-iron oxide composite nanoparticles for EPR-independent drug delivery. Biomaterials (2016) 0.79
Computational simulations of magnetic particle capture in arterial flows. Ann Biomed Eng (2009) 0.79
Smart Magnetically Responsive Hydrogel Nanoparticles Prepared by a Novel Aerosol-Assisted Method for Biomedical and Drug Delivery Applications. J Nanomater (2011) 0.79
Distribution and accumulation of Cy5.5-labeled thermally cross-linked superparamagnetic iron oxide nanoparticles in the tissues of ICR mice. J Vet Sci (2013) 0.79
Synthesis, characterization, and antimicrobial activity of an ampicillin-conjugated magnetic nanoantibiotic for medical applications. Int J Nanomedicine (2014) 0.79
Nanomedicine: Silence the target. Nat Nanotechnol (2009) 0.79
Dynamic inversion enables external magnets to concentrate ferromagnetic rods to a central target. Nano Lett (2014) 0.79
Magnetic Properties of Polyvinyl Alcohol and Doxorubicine Loaded Iron Oxide Nanoparticles for Anticancer Drug Delivery Applications. PLoS One (2016) 0.78
Externally Applied Static Magnetic Field Enhances Cardiac Retention and Functional Benefit of Magnetically Iron-Labeled Adipose-Derived Stem Cells in Infarcted Hearts. Stem Cells Transl Med (2016) 0.78
Nanocarriers Usage for Drug Delivery in Cancer Therapy. Iran J Cancer Prev (2016) 0.78
Real-time monitoring of magnetic drug targeting using fibered confocal fluorescence microscopy. J Control Release (2016) 0.78
Magnetic nanoparticles and nanocomposites for remote controlled therapies. J Control Release (2015) 0.78
Bench-to-bedside translation of magnetic nanoparticles. Nanomedicine (Lond) (2014) 0.77
Transport characteristics of nanoparticle-based ferrofluids in a gel model of the brain. Int J Nanomedicine (2009) 0.77
Synthesis and characterization of noscapine loaded magnetic polymeric nanoparticles. J Magn Magn Mater (2010) 0.76
Modelling the effect of SPION size in a stent assisted magnetic drug targeting system with interparticle interactions. ScientificWorldJournal (2015) 0.76
Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. Nanomedicine (Lond) (2014) 0.76
Planar Steering of a Single Ferrofluid Drop by Optimal Minimum Power Dynamic Feedback Control of Four Electromagnets at a Distance. J Magn Magn Mater (2011) 0.76
Remote magnetic targeting of iron oxide nanoparticles for cardiovascular diagnosis and therapeutic drug delivery: where are we now? Int J Nanomedicine (2016) 0.75
Electrochemical synthesis of magnetic iron oxide nanoparticles with controlled size. J Nanopart Res (2011) 0.75
Mechanistic understanding of toxicity from nanocatalysts. Int J Mol Sci (2014) 0.75
Manipulation of magnetic nanoparticle retention and hemodynamic consequences in microcirculation: assessment by laser speckle imaging. Int J Nanomedicine (2012) 0.75
Perspective of Fe3O4 Nanoparticles Role in Biomedical Applications. Biochem Res Int (2016) 0.75
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
Hyperthermia in combined treatment of cancer. Lancet Oncol (2002) 4.41
Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood (1997) 4.36
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest (1997) 3.22
Locoregional cancer treatment with magnetic drug targeting. Cancer Res (2000) 3.05
Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med (1997) 2.88
Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther (2002) 2.86
Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med (1991) 2.40
Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res (1996) 2.35
Clinical applications of magnetic drug targeting. J Surg Res (2001) 2.25
Post-transcriptional regulation of interleukin-6 gene expression in human keratinocytes by ultraviolet B radiation. J Invest Dermatol (1994) 2.09
Resection of liver metastases in colorectal cancer--competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol (1990) 2.07
Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 2.06
Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol (1993) 2.02
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol (2003) 2.01
Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest (1996) 2.00
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia (2005) 1.95
Acute pancreatitis and normoamylasemia. Not an uncommon combination. Ann Surg (1989) 1.94
Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med (1985) 1.87
Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells. Oncogene (2006) 1.86
NEW PENETRATING VEHICLES AND SOLVENTS. Science (1942) 1.86
Neuronal expression of the NADPH oxidase NOX4, and its regulation in mouse experimental brain ischemia. Neuroscience (2005) 1.84
High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood (1996) 1.82
Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood (1998) 1.80
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia (2013) 1.77
CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol (1987) 1.76
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Neonatal neutropenia in low birthweight premature infants. Am J Perinatol (1995) 1.74
Value of internal limiting membrane peeling in surgery for idiopathic macular hole stage 2 and 3: a randomised clinical trial. Br J Ophthalmol (2008) 1.73
Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol (2004) 1.73
Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene (1999) 1.71
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Mucormycoses. Mycoses (2001) 1.70
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol (1998) 1.68
Apoptosis: implications of basic research for clinical oncology. Lancet Oncol (2001) 1.68
Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia (1998) 1.67
Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg (2010) 1.65
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer (2005) 1.65
[Magnetic Drug Targeting--a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies]. HNO (2005) 1.64
High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood (1989) 1.64
HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol (1986) 1.63
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer (2009) 1.62
Normal values for respiratory resistance using forced oscillation in subjects>65 years old. Eur Respir J (2005) 1.61
Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer (2003) 1.60
Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood (1998) 1.59
Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol (2010) 1.59
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood (2000) 1.55
Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood (1999) 1.53
Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry (2001) 1.52
Fastest reduction of posttraumatic edema: continuous cryotherapy or intermittent impulse compression? Foot Ankle Int (1997) 1.52
Granulocyte/macrophage colony-stimulating factor induces interleukin 1 production by human polymorphonuclear neutrophils. J Immunol (1988) 1.51
Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem (2000) 1.50
A clinical pilot study of fresh frozen plasma versus human albumin in paediatric craniofacial repair. J Int Med Res (2008) 1.48
Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 1.48
Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int (2002) 1.47
Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol (2005) 1.45
Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer (1999) 1.44
Is a single oral dose of ivermectin sufficient in crusted scabies? Int J Dermatol (2001) 1.44
Towards a better definition of human leucocyte surface molecules. Immunol Today (1989) 1.42
Selective susceptibility of CD34-expressing cells to acquire flow cytometric features of apoptosis/necrosis on exposure to an ammonium chloride-based red blood cell lysing reagent. J Hematother (1998) 1.42
Interference of blood leucocytes in the measurements of immature red cells (reticulocytes) by two different (semi-) automated flow-cytometry technologies. Clin Lab Haematol (1996) 1.42
[Use of high resolution color Doppler sonography in diagnosis of temporal arteritis]. Rofo (1998) 1.41
Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut (2009) 1.40
Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol (1999) 1.40
Diagnosis and treatment of AL amyloidosis. Clin Nephrol (2000) 1.40
Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells. Blood (1996) 1.40
[Postoperative nuclear magnetic resonance tomography of the talocrural joint after external syndesmorrhaphy]. Rofo (1991) 1.40
[Antimicrobial therapy in neutropenia]. Dtsch Med Wochenschr (1997) 1.40
Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ (2006) 1.39
APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol (1993) 1.39
Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol (1994) 1.39
The intubation scoop (i-scoop) - a new type of laryngoscope for difficult and normal airways. Anaesthesia (2014) 1.39
[Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapsone therapy]. Hautarzt (1993) 1.39
Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol (1995) 1.39
Subtypes of T-cell chronic lymphatic leukemia. Cancer (1983) 1.39
PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat (2003) 1.39
[Diagnostic and therapeutic management of patients receiving antithrombotic drugs: what to heed?]. Dtsch Med Wochenschr (2006) 1.38
The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins. Mol Cell Biol (1996) 1.38
Uveal melanoma: detection of extraocular growth with MR imaging and US. Radiology (1997) 1.38
[Project graph technique for time management in abdominal ultrasound evaluations]. Ultraschall Med (1999) 1.38
Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. Cancer J Sci Am (2006) 1.38
Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol (1996) 1.38